Vaxcyte, Inc.
PCVXNasdaqHealthcare · Biological Products, (No Diagnostic Substances) · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — |
| Operating income | −$923.7M | −$569.5M | −$468.0M | −$232.3M | −$103.7M | −$27.6M |
| Net income | −$766.6M | −$463.9M | −$402.3M | −$223.5M | −$100.1M | −$27.1M |
| Total assets | $3.00B | $3.51B | $1.41B | $1.01B | $324.3M | $392.8M |
| Total liabilities | $317.2M | $205.5M | $167.4M | $52.6M | $40.3M | $47.0M |
| Equity | $2.69B | $3.31B | $1.24B | $953.6M | $284.0M | $345.8M |
| EPS (diluted) | $-5.63 | $-3.80 | $-4.14 | $-3.44 | $-1.93 | $-3.02 |
| Shares out. | 128.8M | 108.4M | 80.0M | 56.3M | 51.3M | 51.1M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- —
- Net margin
- —
- Return on equity
- −28.5%
- Return on assets
- −25.5%
- Return on capital (ROCE)
- −33.0%
- Liabilities / assets
- 10.6%
- Debt / equity
- 0.12×
- Book value / share
- $20.86
- Revenue growth (YoY)
- —
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- 7.59safe
- Accruals / assets
- −3.7%clean
- Piotroski F-Score
- 1/7weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast. What these scores mean →
Signs
● 1 warning● 3 good- Negative operating cash flow
- Conservative leverage (liabilities < 50% of assets)
- Clean earnings (low accruals)
- Altman Z″ in the safe zone
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Clinical trials
ClinicalTrials.gov · ongoing · next readout first- Phase 3Active Not Recruitingreadout ~2027-01Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Immunobridging to Adults 18-49
- Phase 3Active Not Recruitingreadout ~2027-03A Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 With Influenza Vaccine in Adults ≥ 50 Years of Age
- Phase 3Active Not Recruitingreadout ~2027-03Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Prior Pneumococcal Vaccination
- Phase 1Not Yet Recruitingreadout ~2027-12A Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-A1 in Healthy Young Adults
- Phase 2Active Not Recruitingreadout ~2027-12A Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 in Healthy Infants
Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Ra Capital Management, L.P.Passive (13G)May 15, 2026
- Janus Henderson Group PlcPassive (13G)May 15, 2026
- Fmr LlcPassive (13G)May 6, 2026
- Vanguard Capital Management LlcPassive (13G)Apr 30, 2026
- Vanguard Group IncPassive (13G)Mar 27, 2026
- T. Rowe Price Investment Management, Inc.Passive (13G)Feb 17, 2026
- Blackrock, Inc.Passive (13G)Apr 17, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Wassil JimOfficer — CHIEF OPERATING OFFICER | May 1, 2026 | Sell | 2,250 | $56.83 |
| Cowan ElviaOfficer — SVP, Finance & CAO | Apr 7, 2026 | Option exercise | 3,000 | $25.92 |
| Wassil JimOfficer — CHIEF OPERATING OFFICER | Apr 1, 2026 | Sell | 1,412 | $58.14 |
| Cowan ElviaOfficer — SVP, Finance & CAO | Mar 17, 2026 | Sell | 1,487 | $55.39 |
| Dhaliwal Harpreet S.Officer — Chief Technical Ops Officer | Mar 9, 2026 | Tax withholding | 604 | $59.32 |
| Pickering GrantOfficer — CHIEF EXECUTIVE OFFICER | Mar 9, 2026 | Tax withholding | 3,685 | $59.32 |
| Guggenhime AndrewOfficer — PRESIDENT AND CFO | Mar 9, 2026 | Tax withholding | 1,021 | $59.32 |
| Cowan ElviaOfficer — SVP, Finance & CAO | Mar 9, 2026 | Tax withholding | 495 | $59.32 |
| Wassil JimOfficer — CHIEF OPERATING OFFICER | Mar 9, 2026 | Tax withholding | 975 | $59.32 |
| Cowan ElviaOfficer — SVP, Finance & CAO | Feb 26, 2026 | Grant | 10,681 | $0.00 |
| Guggenhime AndrewOfficer — PRESIDENT AND CFO | Feb 26, 2026 | Grant | 44,864 | $0.00 |
| Pickering GrantOfficer — CHIEF EXECUTIVE OFFICER | Feb 26, 2026 | Grant | 105,110 | $0.00 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 13.8M | 7.8 | -2.5% |
| Apr 30, 2026 | 14.1M | 13.1 | -1.5% |
| Apr 15, 2026 | 14.4M | 11.8 | +4.9% |
| Mar 31, 2026 | 13.7M | 9.8 | +4.7% |
| Mar 13, 2026 | 13.1M | 10.9 | -1.4% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Results of operationsMay 6, 2026
- Other material eventFeb 24, 2026
- Results of operationsFeb 24, 2026
- Other material eventFeb 2, 2026
- Director / officer changeDec 19, 2025
- Results of operationsNov 4, 2025
- Entered a material agreementSep 30, 2025
- Results of operationsAug 6, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- 144Jun 1, 2026
- SCHEDULE 13G/AMay 15, 2026
- SCHEDULE 13G/AMay 15, 2026
- 10-QMay 6, 2026
- 8-KMay 6, 2026
- SCHEDULE 13G/AMay 6, 2026
- 4FORM 4May 1, 2026
- 144May 1, 2026
- SCHEDULE 13GApr 30, 2026
- ARSApr 23, 2026
- DEFA14AApr 23, 2026
- DEF 14AApr 23, 2026
- 4FORM 4Apr 8, 2026
- 144Apr 7, 2026
- 4FORM 4Apr 3, 2026
Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.